Navigation Links
GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives

- Company To Actively Pursue Acquisition Opportunities -

BRIDGEWATER, N.J. and NEW YORK, June 18 /PRNewswire/ -- GANIC Pharmaceuticals, a new specialty pharmaceutical company, today announced its launch backed by Warburg Pincus, the leading global private equity firm. Warburg Pincus has made an initial investment in GANIC from Warburg Pincus Private Equity X, L.P., a $15 billion fund, which closed in April.

GANIC Pharmaceuticals was founded by a highly seasoned group of senior executives with 65 years of collective experience in the pharmaceutical industry, in partnership with Warburg Pincus. The company's founders include Paul Edick, Chief Executive Officer, Chief Financial Officer Corey Fishman, and Chief Commercial Officer Chris Maltese, all formerly senior executives at MedPointe Pharmaceuticals.

Paul Edick, CEO of GANIC Pharmaceuticals, said, "We see tremendous opportunities for profitable growth and expansion across our targeted areas of focus. We believe that we have the expertise, industry networks, talent base and funding to begin executing towards our objectives. We are very pleased to have as our sole investor, Warburg Pincus, a firm with great insight and expertise in our arena, which shares our strategic vision to build a great company."

GANIC Pharmaceuticals will focus on building a substantial enterprise by acquiring revenue-generating companies, portfolios and/or products and by investing in innovation and acquiring pipeline development assets. GANIC plans to target certain specialty pharmaceutical areas.

Commenting on the investment, Jonathan S. Leff, a Managing Director of Warburg Pincus, stated, "We are delighted to partner with the GANIC team, which has a proven track record for delivering value to investors and the pharmaceutical marketplace. We are confident that their strategy and ability to execute effectively, when combined with our funding and strategic support, will enable them to build a substantial and important pharmaceutical company." In conjunction with this investment, Mr. Leff, Managing Director Stewart Hen and Principal Cecilia Gonzalo of Warburg Pincus will join GANIC Pharmaceuticals' board of directors.

About GANIC Pharmaceuticals

Based in New Jersey, GANIC Pharmaceuticals is a new specialty pharmaceutical company, founded by a highly seasoned group of senior executives with 65 years of collective experience in the pharmaceutical industry, in partnership with Warburg Pincus, a leading global private equity firm. The company is focused on building a fully-integrated pharmaceuticals enterprise focused on certain specialty areas.

About Warburg Pincus

Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $35 billion of assets under management. Warburg Pincus' investments are focused on a range of sectors in North America, Europe and Asia, including financial services, healthcare, industrial, technology, media and telecommunications, energy, consumer and retail and real estate. Since inception, the firm has raised 12 private equity funds that have invested more than $31 billion in approximately 600 companies in more than 30 countries. The firm has invested $6.6 billion in healthcare-related companies around the world, including approximately $1.6 billion to help build nearly 40 biotechnology and pharmaceutical companies. The firm has an active global portfolio of more than 125 companies and offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, visit

Business Inquiries

Corey Fishman

GANIC Pharmaceuticals


Media Inquiries

Todd Fogarty or Joseph Kuo

Kekst and Company

212-521-4800 or

SOURCE GANIC Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials
2. SAFC Hitech Launches Metalorganic Bulk Vapor Distribution System for Compound Semiconductor Manufacturing
3. Directed self-ordering of organic molecules for electronic devices
4. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
5. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
8. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
9. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
10. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
11. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Post Your Comments:
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
(Date:11/24/2015)... Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, will present at ... week in New York City . The ... December 1, 2015 at 9:30 a.m. EST. ... the website at least 15 minutes prior to the presentation ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce that ... facility will be strictly dedicated to basic USP 61, USP 62 and USP 51 ... to have complete chemistry and micro testing performed by one supplier. Management ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
Breaking Biology Technology:
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):